Destiny Pharma plc

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. We have two exciting late-stage clinical assets and a range of earlier research programmes. Our pipeline includes assets being developed from our own XF platform and two biotherapeutic products that harness specific components of the human microbiome. Our lead asset, NTCD-M3, targets CDI. The company owns global rights to the world’s most advanced single strain, live bio-therapeutic product which is the non-toxigenic Clostridioides difficile strain M3 – for the prevention of recurring C. difficile gut infections (CDI). NTCD-M3 has already delivered world leading clinical efficacy data in a successful Phase 2 trial where the infection recurrence rate in NTCD-M3 treated patients was just 5%, compared to those on placebo where the infection recurrence rate was 30%.